| PYC Stock | | | 1.40 0.05 3.45% |
Altman Z Score is one of the simplest fundamental models to determine how likely your company is to fail. The module uses available fundamental data of a given equity to approximate the Altman Z score. Altman Z Score is determined by evaluating five fundamental price points available from the company's current public disclosure documents. Check out
Your Equity Center to better understand how to build diversified portfolios, which includes a position in PYC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in board of governors.
At this time, PYC Therapeutics'
Net Invested Capital is comparatively stable compared to the past year.
Net Working Capital is likely to gain to about 80.3
M in 2024, whereas
Capital Expenditures is likely to drop slightly above 224.6
K in 2024. At this time, PYC Therapeutics'
Interest Income is comparatively stable compared to the past year.
Net Interest Income is likely to gain to about 784.1
K in 2024, despite the fact that
EBIT is likely to grow to (37.2
M).
PYC Therapeutics Company Z Score Analysis
PYC Therapeutics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| First Factor | = | 1.2 * ( | Working Capital | / | Total Assets ) |
|
| Second Factor | = | 1.4 * ( | Retained Earnings | / | Total Assets ) |
|
| Thrid Factor | = | 3.3 * ( | EBITAD | / | Total Assets ) |
|
| Fouth Factor | = | 0.6 * ( | Market Value of Equity | / | Total Liabilities ) |
|
| Fifth Factor | = | 0.99 * ( | Revenue | / | Total Assets ) |
|
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
Based on the company's disclosures, PYC Therapeutics has a Z Score of 0.0. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as
Health Care (which currently averages 0.0) industry. This indicator is about the same for all Australia stocks average (which is currently at 0.0).
| | Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
PYC Fundamentals
About PYC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PYC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PYC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of PYC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for PYC Stock Analysis
When running PYC Therapeutics' price analysis, check to
measure PYC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PYC Therapeutics is operating at the current time. Most of PYC Therapeutics' value examination focuses on studying past and present price action to
predict the probability of PYC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PYC Therapeutics' price. Additionally, you may evaluate how the addition of PYC Therapeutics to your portfolios can decrease your overall portfolio volatility.